On the 23rd of May, Jan De Backer – CEO of Fluidda had an interview with Edwin Warfield – CEO of Citybiz.
Introduction | Please provide an introduction to Fluidda? Employees, locations, products. What is a clinical research services company?
Respiratory Imaging in the Age of Covid | Can you explain the complexity of lung diseases and current diagnostic capabilities? What are the weaknesses of conventional CT scans? Can you explain functional respiratory imaging?
Impact | Please explain the potential impact on asthma and other respiratory diseases? How is Fluidda impacting drug development?
Machine Learning | What role does machine learning play in technology?
Personalized Medicine | How is Fluidda part of personalized medicine?
Experience | How many clinical centers have been trained worldwide? Clinical studies in disease characterization and therapy analysis?
Spinout | Tell us about how Fluidda was spun off out of the University of Antwerp?
Milestones | You have been CEO of Fluidda for 15 years. Can you share some of the major milestones?
FDA | In 2020 the US Food and Drug Administration provides market clearance to Fluidda for its Broncholab platform.
Capital | How has Fluidda been funded to date? Can you tell us about the partnership with Materialise?
Growth | What are the growth plans for Fluidda?
CEO, Citybiz, Interview